Use of a novel cytotoxic HEXIM1 peptide in the directed breast cancer therapy

Supplementary Materials
Supplementary Figure S1: FGF-BR peptide induced rapid cytotoxicity to cells. HCT116 cells were plated on 4-chamber glass cover slides (Lab-Tek) to attach overnight at appropriate density to achieve 50% confluence the next day. FGF-tagged X13 or BR peptides (30 µM) was added to the cells. Microscopic time-lapse images were taken every 30 seconds for 30 mins at 37°C. Images were acquired on a Nikon Eclipse Ti inverted microscope, equipped with a Plan Apo VC 60X/1.4 NA DIC oil immersion objective lens, the Perfect Focus System (to maintain focus during time-lapse experiments), a motorized stage, an X-cite 120PC Q metal halide fluorescence lamp (Lumen Dynamics), a pE-100 transmitted lamp (cooLED) and a Coolsnap HQ2 CCD camera (Photometrics). Samples were incubated in a stage-top incubator with humidified chamber (Live-Cell Instruments) at 37°C and 5% CO 2 . The multidimensional data acquisition was controlled by MetaMorph software (Molecular Devices). Figure S2 : LTV-tagged BR peptide required all three stretches of basic residues to establish full potency in cell killing. MDA-MB-231 breast cancer cells were treated with indicated truncated LTV-fused peptides at various concentrations overnight before cell viability assays were performed. Cells treated with LTV-X13 was used as a negative control. Data representative of at least three independent experiments performed in triplicate were shown with values expressed as mean ± SD.
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